Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IXINITY in Pediatric Hemophilia B
NCT01271868Phase 3Terminated
- Sponsor
- Medexus Pharmaceuticals
- Start
- Nov 2010
- Primary completion
- Dec 2016
- Countries
- 3
01
Overview
A Phase 3 trial of coagulation factor ix recombinant in hemophilia B (HB), sponsored by Medexus Pharmaceuticals. Started Nov 2010; status: terminated.
02
Drugs
coagulation factor ix recombinant
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT01271868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01271868.